Reactions 1680, p204 - 2 Dec 2017 Anxiety with recurrence and aggravation of night terror: case report A 23-year-old man experienced anxiety with recurrence and aggravation of night terror during treatment with lisdexamfetamine [route, dosage and indication not stated]. The man, who had a history of childhood night terrors, reported recurrence of night terror just a month after the initiation of lisdexamfetamine therapy. During childhood, he used to had night terrors at an interval of three to four times per year, whereas currently he was experiencing recurrence three to five times per week. At presentation, he had a BP of 140/96 and a pulse of 105 [units not stated]. His mental status examination showed anxious mood with congruent affect. On anamnesis, he reported night terror as a black figure appearing next to the door or the bed. At that time, he was unable to speak or to move. Then, he shouted loudly. Thereafter, his parents woke him up from terror sleep [outcomes not stated]. Author comment: "Possibly, [lisdexamfetamine] acted to precipitate night terrors by functioning as a dopamine receptor agonist." "Lisdexamfetamine may be inducing night terror indirectly through enhancement of anxiety." Makwana MN, et al. The incubus strikes again: Recurrence of sleep terrors with lisdexamfetamine administration. CNS Spectrums 22: 84-85 (plus poster) abstr. 140, No. 1, 7 Feb 2017. Available from: URL: http://doi.org/10.1017/ S1092852916000900 [abstract] - India 803284805 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud